Rangwala Reshma 4

What Happened

• Reshma Rangwala, Executive Vice President & Chief Medical Officer of Karyopharm Therapeutics Inc. (KPTI), received a grant of 32,415 restricted stock units (RSUs) on January 31, 2026. The Form 4 reports the award as an acquisition (transaction code A) at $0.00 per share (RSUs are awards, not purchases).

Key Details

• Transaction date: 2026-01-31; Filing date (Accession): 2026-02-03.
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 32,415 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The RSUs were granted under the 2022 Equity Incentive Plan and convert one-for-one into common stock. Vesting: 50% on Jan 31, 2027 and 50% on Jan 31, 2028 (see F1).
• Timeliness: Filing does not indicate lateness; transaction dated Jan 31 and filed Feb 3, 2026.

Context

• RSU grants are compensatory awards and are different from open-market purchases or sales; they typically vest over time and therefore do not necessarily signal immediate insider buying or selling. Upon vesting the RSUs convert to shares (and may be subject to tax withholding per plan rules).